Taudia’s SPLASH™ platform provides ultrasensitive protein quantification by using dual‑conjugated antibody probes and a wash‑based proximity ligation assay, with readout on standard qPCR instruments. The workflow detects femtogram‑per‑milliliter concentrations in blood within four hours, and can be run manually or on the automated NeuXplore™ system for scalable biomarker validation and diagnostic testing.
Funding
Funding not disclosed
Founders
Product
Problem
Detecting low‑abundance protein biomarkers in blood, such as neurodegenerative disease markers, is limited by the sensitivity of conventional immunoassays and often requires complex, expensive instrumentation, hindering early diagnosis and large‑scale research.
Solution
Taudia’s SPLASH™ platform delivers ultrasensitive protein quantification by combining a dual‑conjugated antibody probe with a wash‑based proximity ligation assay. The workflow captures immunocomplexes, removes unbound material, ligates DNA tags, and quantifies them via standard qPCR, enabling detection of femtogram‑per‑milliliter concentrations. The method works on any existing qPCR instrument, requiring no specialized hardware, and can be performed manually or fully automated with the NeuXplore™ sample‑to‑answer system. Results are reported in pg/mL within four hours, supporting both low‑throughput benchtop use and high‑throughput automated runs. This flexible, scalable solution accelerates biomarker validation, patient screening, and companion diagnostic development for neurodegenerative diseases and other conditions.
Target Audience
Primary customers are biopharma companies, contract research organizations, and academic laboratories developing or validating protein biomarkers for neurodegenerative diseases, as well as clinical labs seeking rapid, blood‑based diagnostic tests.
Features
- Dual‑conjugated antibody probes that capture target proteins and enable selective immunocomplex isolation
- One‑wash proximity ligation workflow that eliminates background interference and simplifies assay steps
- DNA ligation and release followed by qPCR or dPCR quantification, leveraging existing laboratory equipment
- Compatibility with any qPCR platform for low‑cost, low‑barrier implementation
- Fully automated NeuXplore™ benchtop instrument (FDA Class II) delivering sample‑to‑answer results in <4 hours, with 16‑48 sample capacity per run
- Scalable manual kit option for flexible throughput and budget‑conscious labs
- Quantitative output in pg/mL with demonstrated linearity down to fg/mL and high specificity (80‑120 % recovery)